| Editor’s Note: The Fierce Life Sciences Weekly Digest will not publish next week, November 24, in observance of the U.S. Thanksgiving holiday. Thank you for reading, and we’ll be back in your inboxes December 1. |
| By Fraiser Kansteiner Pfizer plans to cut approximately 500 roles and ax its Pharmaceutical Sciences Small Molecule capabilities at its site in Sandwich in Kent in the U.K. The move is a consequence of Pfizer’s enterprisewide cost realignment program, which the drugmaker unveiled in mid-October. |
|
|
|
By James Waldron Novartis is going to give a solid-tumor-focused cell therapy the T-Charge treatment after paying $100 million upfront to Legend Biotech for a selection of CAR-T candidates. |
By Ben Adams Eli Lilly nabbed a coveted FDA approval for its obesity drug this month and, despite using the same ingredient as its diabetes drug Mounjaro, the U.S. Big Pharma has created a dividing line between the two franchises. |
By Kevin Dunleavy How popular have Novo Nordisk’s semaglutide drugs become for weight loss in Europe? The craze is such that Germany’s drug regulator is considering banning the export of Ozempic, according to a report in Der Spiegel magazine. |
By Max Bayer A day after AstraZeneca inked a new $185 million licensing deal to reenter the GLP-1 frenzy, CEO Pascal Soriot says the future marketplace will center less on treating obesity and more on sustained weight management. |
By Angus Liu In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival. |
By Angus Liu As demand continues to surge for the Ozempic-Wegovy duo of diabetes and obesity meds, Novo Nordisk is investing heavily to boost production capacity with a new trench worth more than $6 billion. |
By Nick Paul Taylor Verve Therapeutics has published the first data on an in vivo base editing program in humans, giving the world an early look at the effects of a cholesterol-busting candidate that could become part of Eli Lilly’s stable of heart disease drugs. But investors pummeled the stock amid potential safety concerns. |
By Andrea Park The C-suite makeover is aimed at emphasizing ResMed’s focus on product development, profitable growth and strengthened branding, according to a company announcement. |
By Helen Floersh Researchers have reported the first-ever live birth of a chimeric monkey developed largely from embryonic stem cells. While the advancement is a technical achievement, it also raises ethical concerns. |
By Angus Liu A few months ago, Fierce Pharma asked employees working in the biopharma industry to use photographs to tell their stories during the pandemic. Now, we’re showcasing those precious memories here. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of "Podnosis," you'll hear from two journalists from the Fierce Healthcare team: Paige Minemyer, senior editor of Fierce Health Payer, and Dave Muoio, a staff writer for Fierce Healthcare. Together, they guide you through their key insights from the inaugural Fierce Health Payer Summit in Austin and dive into the latest earnings updates from the largest health plans and health systems. |
|
|---|
|
|
|
Tuesday, November 21, 2023 | 10am ET / 7am PT Join this webinar to keep your organization at the forefront of the pharma industry's tech evolution and ensure you and your team are well-prepared for what lies ahead and learn how to navigate and leverage the commercial technology ecosystem to drive real transformation. Register now.
|
|
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| WhitepaperDSCSA Compliance with a Trusted Partner Sponsored by: BioCare |
| WhitepaperYour guide to accessing, managing, and licensing the content that fuels AI, machine learning, and data visualization projects across the enterprise. Sponsored by: CCC |
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperIs pharma spending money on the wrong types of AI? Here’s how real-time clinical alerts could change the minds of the world’s top commercial leaders. Sponsored by: Viz.Ai |
| WhitepaperWant to know the Top 5 criteria for selecting the ‘right’ CDMO for pDNA manufacturing? Sponsored by: Syngene |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
